Viridian Therapeutics, Inc.
VRDN
$12.30
-$0.51-3.98%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -86.91M | -79.73M | -76.69M | -64.99M | -48.54M |
| Total Depreciation and Amortization | 117.00K | 23.00K | 930.00K | 142.00K | 145.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.00M | 5.91M | 5.09M | 7.67M | 8.13M |
| Change in Net Operating Assets | -13.86M | 460.00K | 2.97M | 11.13M | -4.96M |
| Cash from Operations | -92.65M | -73.33M | -67.71M | -46.06M | -45.22M |
| Capital Expenditure | -86.00K | -114.00K | -293.00K | -104.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.15M | -62.80M | -84.37M | 62.08M | -143.05M |
| Cash from Investing | 100.06M | -62.92M | -84.67M | 61.98M | -143.05M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9.42M | 36.83M | 235.18M | 210.00K | 187.46M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 0.00 | 25.00M | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -207.00K | -1.31M | -15.15M | -102.00K | -10.38M |
| Cash from Financing | 9.21M | 35.52M | 245.02M | 108.00K | 177.08M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.62M | -100.72M | 92.65M | 16.03M | -11.19M |